- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03676335
Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye
A Phase Ⅱ, Multicenter, Randomized, Single-blind, Positive-controlled, Dose-finding Study to Assess the Efficacy and Safety of CsA Ophthalmic Gel in Subjects With Moderate to Severe Aqueous-Deficient Dry Eye (ADDE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A multicenter, randomized, single-blind, positive controlled exploratory study will be conducted with cyclosporine A ophthalmic emulsion as the control drug.
The experimental drugs were divided into three groups:
Treatment group A: CsA eye gel: 0.3 g: 0.15 mg, once daily; Treatment group B: CsA eye gel: 0.3 g: 0.15 mg, twice daily, interval of about 12 hours; Treatment group C: CsA eye gel: 0.3 g: 0.3 mg, once daily. One drop into each eye when you use it.
Control group: CsA emulsion: 0.4 ml: 0.2 mg. One drop into the eye, 2 times daily with an interval for 12 hours.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Ophthalmological Center of Zhongshan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18, both male and female;
- Pregnancy tests were negative for women of childbearing age and contraceptive measures (including abstinence, intrauterine devices, diaphragms and spermicides) were taken during the trial. Men are willing to use approved contraceptive methods (possibly using condoms and spermicides or oral contraceptives, implants or injections of contraceptives, intrauterine devices, diaphragms and spermicides) or sexual partner infertility;
According to the symptoms and signs and ophthalmologic examinations, the patients were diagnosed as moderate to severe dry eye;
- EDS score is more than 40 points;
- BUT is less than 10 s;
- Schirmer test result is less than 10mm/5 min;
- In any area, corneal fluorescein staining was more than 2 points.
- The anatomy of the eyelids is normal and has normal blinking function;
- Patients with newly diagnosed dry eye disease, or who are undergoing dry eye treatment, voluntarily discontinue treatment within 72 hours of entering the screening period;
- Ability and willingness to participate in all research assessments and all planned visits during the pilot period in accordance with the programme requirements;
- Agree to participate in the study and voluntarily sign informed consent.
Exclusion Criteria:
- Allergy to CsA, fluorescein or any component of the drug is known;
- Severe dry eye patients requiring surgical treatment;
- Glaucoma patients;
- Unwilling to avoid wearing contact lenses;
- Within 12 months prior to the start of the study, intraocular surgery or internal surgery was necessary;
- Eyelid surgery was performed within 6 months prior to the start of the study, or dry eye secondary to surgery;
- Those who had undergone corneal refractive surgery or keratoplasty;
- Congenital lacrimal gland or meibomian gland deficiency or lacrimal gland obstructive diseases;
- Systemic inflammation or active eye infection and blepharitis;
- Patients with ocular cicatricial pemphigoid, obvious conjunctival scar, ocular chemical burn and neurotrophic keratoconjunctivitis;
- Who suffered from ocular malignancies;
- No other eye drops could be stopped during the study period;
- Systemic or uncontrollable disorders that affect the collection of research parameters or patient compliance, such as severe cardiopulmonary disease, uncontrollable hypertension and diabetes;
- With history of central nervous system disease or epilepsy, and / or mental disorder;
- Pregnant women and lactating women, or women of childbearing age, do not adopt effective contraceptive measures;
- Participated in other clinical trials or participated in other clinical trials within 1 months before the election;
- Systemic or topical cyclosporine drugs within 3 months;
- Patients who were not considered suitable for the study, including those who were unable or unwilling to comply with the protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.3 g: 0.15 mg(1)&Hypromellose Eye Drops
Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks.
The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
|
The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
Other Names:
Hypromellose Eye Drops of 15ml:75mg, 3 times daily, 1-2 drop
Other Names:
|
Experimental: 0.3 g: 0.15mg(2)&Hypromellose Eye Drops
Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks.
The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
|
The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
Other Names:
Hypromellose Eye Drops of 15ml:75mg, 3 times daily, 1-2 drop
Other Names:
|
Experimental: 0.3 g: 0.3 mg &Hypromellose Eye Drops
Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks.
The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
|
The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
Other Names:
Hypromellose Eye Drops of 15ml:75mg, 3 times daily, 1-2 drop
Other Names:
|
Active Comparator: 0.4 ml: 0.2 mg &Hypromellose Eye Drops
Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks.
The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
|
Hypromellose Eye Drops of 15ml:75mg, 3 times daily, 1-2 drop
Other Names:
The CsA for eye emulsion of 0.4 ml: 0.2 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The EDS score at the NO.5 visit was compared with the baseline EDS score (binocular)
Time Frame: 84 days after admission
|
0-100 points VAS score was evaluated
|
84 days after admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average changes in VAS scores of 6 dry eye symptoms (burning/needling sensation, pruritus, foreign body sensation, discomfort, photophobia and pain) at the NO.3, NO.4 and NO.5 visit were compared with baseline (binocular)
Time Frame: 14 days after admission ,42 days after admission ,84days days after admission
|
0-100 points VAS score was evaluated
|
14 days after admission ,42 days after admission ,84days days after admission
|
The EDS score at the NO.3, NO.4 visit were compared with the baseline EDS score (binocular)
Time Frame: 14 days after admission ,42days after admission
|
0-100 points VAS score was evaluated
|
14 days after admission ,42days after admission
|
Comparison of the NO.3, NO.4, NO.5 visit and baseline corneal fluorescein staining changes
Time Frame: 14 days after admission ,42 days after admission ,84 days after admission
|
score(The cornea was divided into five quadrants: central, upper, lower, temporal and nasal.
The cornea was stained with 4 points, 0 points for non-staining, 1 point for scattered dotted staining, 2 points for clan staining, 3 points for local dense + scattered dotted staining and 4 points for extensive diffuse staining.
The total score is the sum of the quadrant scores)
|
14 days after admission ,42 days after admission ,84 days after admission
|
Comparison of the NO.3, NO.4, NO.5 visit and baseline BUT changes
Time Frame: 14 days after admission ,42 days after admission ,84 days after admission
|
time
|
14 days after admission ,42 days after admission ,84 days after admission
|
Comparison of the NO.3, NO.4, NO.5 visit and baseline Schirmer changes
Time Frame: 14 days after admission ,42 days after admission ,84 days after admission
|
Basal tear secretion
|
14 days after admission ,42 days after admission ,84 days after admission
|
Collaborators and Investigators
Investigators
- Study Director: shiyou zhou, PHD, Ophthalmological Center of Zhongshan University
Publications and helpful links
General Publications
- Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2):179-93. doi: 10.1016/s1542-0124(12)70086-1.
- Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002 Mar;120(3):330-7. doi: 10.1001/archopht.120.3.330. Erratum In: Arch Ophthalmol 2002 Aug;120(8):1099.
- Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009 Feb;147(2):206-213.e3. doi: 10.1016/j.ajo.2008.08.015. Epub 2008 Oct 9.
- Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010 Oct;18(5):352-61. doi: 10.3109/09273948.2010.498657.
- Barr JT, Schechtman KB, Fink BA, Pierce GE, Pensyl CD, Zadnik K, Gordon MO. Corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: baseline prevalence and repeatability of detection. Cornea. 1999 Jan;18(1):34-46.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZK-CSA-201704
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on CsA eye gel
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Completed
-
Alcon ResearchCompleted
-
Ophthalmic Consultants of ConnecticutUnknown
-
Novaliq GmbHCompletedDry Eye DiseaseUnited States
-
Novaliq GmbHCompletedDry Eye DiseaseUnited States
-
Horus PharmaUnknown
-
Alcon ResearchCompleted
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
AllerganCompleted
-
Peking Union Medical College HospitalNot yet recruiting